Patients with heart failure with normal ejection fraction (HFNEF) also referred to as ‘stiff heart’, show a normal ejection fraction and severe diastolic dysfunction. President of the Austrian Society of Cardiology, Professor Irene Lang warns: ‘It is particularly concerning that stiff heart is a little known and insufficiently researched cardiac condition -- a stepchild in research,…
Trials for a new type of treatment for stroke that could help millions of people at risk of death or disability should commence in 2011. A research team in France has successfully completed laboratory tests of antibodies that protect the brain and reduce the side-effects of current therapy.
An increase in survival in metastatic melanoma – the cancer with the most rapidly increasing incidence across the EU – has been shown for the first time in a major international study by researchers from across Europe. The results showed that patients who received a novel monoclonal antibody called ipilimumab lived 34% longer than control patients given gp100 peptide vaccine.
To optimise workflow and save costs in hospital pharmacies automating medication selection is increasingly popular. Since the 1980s, the firm Apostore, based in Gelsenkirchen, Germany, a subsidiary of KHT (Kommissionier- und Handhabungstechnik GmbH), has constantly extended its technological lead in this field of manufacturing, and the company reports that its Carryfix Pusher leads the market in…
A multiple sclerosis risk sharing scheme, set up by the Department of Health (DoH) in 2002 to ensure that disease-modifying drugs were available on the National Health Service (NHS), has been deemed ‘a costly failure’, according to researchers reporting on www.bmj.com in June. The scheme, they advise, should not be continued.
European healthcare providers could benefit from savings of over €3.8 billion a year by 2014 as patents expire on leading pharmaceutical products and the market opens up to generics competition, according to latest research from independent market analyst Datamonitor (www.datamonitor.com).
An estimated 9 million children die each year from preventable and treatable causes. A new publication that lists medicines formulated for children is being made available now online by UNICEF and the World Health Organization, to help doctors and organizations obtain some of the 240 essential medicines that can save the lives of children.
New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said. Cancer and cardiovascular disease, both among top U.S. killers, share inflammation as a cause. Heat shock protein 90 inhibitors as a treatment could become additional common ground, said Dr. John Catravas, director of MCG's Vascular Biology Center.
In the Q110 update of “China Pharmaceuticals and Healthcare Report” from Research and Markets, China has maintained its fourth place in the Pharmaceutical Business Environment Ratings matrix for the 15 key markets in the Asia Pacific region. Globally, the country places 18th out of the 71 countries surveyed worldwide, indicating its vast potential. Key attractions are its sheer size and the…
"Cancer can be prevented too" is the theme of a new campaign being launched today in the lead up to World Cancer Day on 4th February, by the International Union Against Cancer (UICC). The campaign is backed by a new scientific report: 'Protection against cancer causing infections' which focuses on the nine infections that can lead to cancer.
The latest analysis of a vaccine’s safety, efficacy and immunogenicity indicates that Cervarix, a human papilloma virus (HPV) vaccine offers sustained protection for over six years against infection by viral types HPV-16 and HPV-18, most commonly associated with cervical cancer.
The Council of Europe member states will launch an inquiry in January 2010 on the influence of the pharmaceutical companies on the global swine flu campaign, focusing especially on extent of the pharma's industry's influence on WHO. The Health Committee of the EU Parliament has unanimously passed a resolution calling for the inquiry.
The German Medical Association aims to evaluate the use of guidelines, the influence of drug companies on studies, the impact of economisation on staff and patients, and ultimately to assess the realities of medical care.
A novel molecular imaging technology aimed at rapid diagnosis of cell death in organs such as the brain and heart has been licensed by The Medical College of Wisconsin, USA, to GE Healthcare. The method uses imaging probes with a radiopharmaceutical compound. Under the license GE will further evaluate and develop the technology and will have an option to commercialize it.
A global vaccination programme against human papilloma virus (HPV), to include boys as well as girls, could lead to eradication of the virus and virtual disappearance of cervical cancer, according to Nobel Prize winner, Professor Emeritus Harald zur Hausen (University of California, San Diego) after recently delivering a keynote lecture at the 16th International Meeting of the European Society of…
Pain is the most common symptom of any illness thus having an alerting function to evoke protective responses. If tissue damage has happened as a consequence of surgery, obstruction, injuries, or cancer a cascade of changes in the peripheral and central nervous system occurs leading to physical inactivation, an increase of morbidity thus delaying hospital stay and treatment costs.
As concern over the potential mutation of the latest form of influenza virus continues to vex governments and their healthcare organisations, WHO 2009 data has shown that acute respiratory infections, influenza and respiratory syncitial virus (RSV) epidemics coincide with epidemics of S. pneumoniae. In fact, half or more of flu-associated mortality in the 1918-1919 Spanish Flu epidemic is…
A global vaccination programme against human papilloma virus (HPV), to include boys as well as girls, could lead to eradication of the virus and virtual disappearance of cervical cancer, predicted Nobel Prize winner, Professor Harald zur Hausen, after delivering the key-note lecture at the 16th International Meeting of the European Society of Gynaecological Oncology (ESGO) in Belgrade, Serbia,…
The biotech industry is being hit twice as hard by the economic crisis. In addition to the general economic downturn, the largely dried-up equity market, which has massively complicated the usual equity financing through the stock exchange or venture capital, is causing problems for companies.
Talking about medical innovations, new drugs, techniques and technologies are the first things that come to mind, whereas new indications for existing pharmaceuticals, especially biological medicines, play a minor role.
The threat of communicable diseases will become even worse in the near future. At the European Health Forum Gastein, the European Union's leading health policy congress for experts and decision-makers, experts stressed that there are a number of risk factors which contribute to a growing risk of the spread of communicable diseases into Europe, namely into the European Union.
Colorectal cancer (CRC) jointly describes cancers of the colon and rectum. Worldwide, CRCs are among the most common cancers. In Europe and the USA the occurrence of CRCs are considerably higher than in Africa and Asia.
The fact that child diabetics (type I) in Russia do not receive necessary and qualitative therapy was again highlighted during the 7th Russian conference 'The priority national project - Health - and the tasks of children's endocrinologists' held in Saint-Petersburg this June.
The Leapfrog Group is a U.S. organisation of member companies that pay for healthcare services, e.g. corporations, health insurers and local, state and federal government agencies. Established in 2000, its philosophy is that big 'leaps' in healthcare safety, quality and value to patients will be recognised and rewarded. The organisation mobilises purchasing power of its members, representing over…
Completion of a Phase I clinical trial has demonstrated the great promise of a completely new type of cancer treatment, according to results announced this June in The New England Journal of Medicine by scientists at the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in the United Kingdom, working with pharma firm AstraZeneca.
